Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Immunotherapy combo improves ORR, PFS in PD-L1+ NSCLC

Key clinical point: Adding tiragolumab to atezolizumab as first-line treatment improves outcomes in PD-L1–positive non–small cell lung cancer.

Major finding: The overall response rate was 37% with tiragolumab/atezolizumab and 21% with placebo/atezolizumab. The median progression-free survival was 5.6 months and 3.9 months, respectively.

Study details: The phase 2 CITYSCAPE study of 135 patients.

Disclosures: The study was sponsored by Genentech. The presenter disclosed relationships with Genentech and numerous other companies.


Rodriguez-Abreu et al. ASCO 2020, Abstract 9503.